Search - tctmd.com

Displaying 1 - 20 of 63

Sort: Relevancy | Date

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

News Daily News

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

December 15, 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

News Conference News AHA 2025

POLY-HF: Polypill Pays Dividends in Patients With HFrEF

November 14, 2025

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

News Features

Cardiac Transplant in Midst of ‘Revolution,’ but Public Trust Is Fragile

Michael O'Riordan

October 17, 2025

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

News Daily News

HYPERION: Sotatercept Helps in PAH Even When Started Earlier in the Disease

October 02, 2025

LAAO May Be an Option for Anticoagulated AF Patients With Breakthrough Stroke

News Daily News

LAAO May Be an Option for Anticoagulated AF Patients With Breakthrough Stroke

September 30, 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

News Conference News ESC 2025

ALONE-AF: Less Bleeding When OAC Stopped After Successful Ablation

September 08, 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

News Conference News ESC 2025

PARACHUTE-HF: Sacubitril/Valsartan Effective in Neglected Chagas Cardiomyopathy

Michael O'Riordan

September 01, 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

News Conference News ESC 2025

Vericiguat Misses Mark in Stable, Well-Treated HFrEF Patients: VICTOR

Michael O'Riordan

August 31, 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

News Conference News ESC 2025

MAPLE-HCM Is a Win, ODYSSEY-HCM Isn’t: Obstructive vs Nonobstructive Divide

August 30, 2025

Starting SGLT2 inhibitors in the Hospital for Acute HF Gains Support

News Conference News ESC 2025

Starting SGLT2 Inhibitors in the Hospital for Acute HF Gains Support

August 30, 2025

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

News Daily News

AI Has Great Potential in CV Pharmacotherapy, but Much Work Lies Ahead: Review

July 24, 2025

Cardiology Consults Tied to Better Outcomes in Patients With HF

News Conference News ESC Heart Failure 2025

Cardiology Consults Tied to Better Outcomes in Patients With HF

May 19, 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

News Conference News ACC 2025

Tight Fluid Restriction Not Needed in Chronic HF Patients: FRESH-UP

Michael O'Riordan

April 01, 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

March 30, 2025

February 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

February 2025 Dispatch for the CV Team

February 01, 2025

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

News Daily News

Change in Kidney Function With Finerenone Doesn’t Impact Treatment’s Benefit

Michael O'Riordan

January 13, 2025

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

News Conference News AHA 2024

REALIZE-K: Potassium Binder Boosts MRA Use in Hyperkalemic HFrEF Patients

November 22, 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

News Conference News AHA 2024

Spironolactone No Help for the Heart After Acute MI: CLEAR SYNERGY

November 17, 2024

SUMMIT: Tirzepatide ‘Huge Win’ for HFpEF Patients With Obesity

News Conference News AHA 2024

SUMMIT: Tirzepatide a ‘Huge Win’ for HFpEF Patients With Obesity

Michael O'Riordan

November 16, 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

News Conference News HFSA 2024

‘Metabolic Accelerator’ Cuts Weight, Not Muscle in HFpEF: HuMAIN-HF

Michael O'Riordan

October 03, 2024

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.